Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jtauto.2020.100062 http://scihub22266oqcxt.onion/10.1016/j.jtauto.2020.100062 32839756!7439010!32839756     free     free     free       J+Transl+Autoimmun 2020 ; ä (ä): 100062 Nephropedia Template TP {{tp|p=32839756|t=2020. Azithromycin: The First Broad-spectrum Therapeutic |pdf=|usr=}}{{32839756}} gab.com Text Azithromycin: The First Broad-spectrum Therapeutic JO: J Transl Autoimmun http://www.kidney.de/pget.php?&tw=1&pmid=32839756 #FOAvip The Strategic Plan for Biodefense Research by the U.S. Department of Health and Human Services demarcates the need for drugs which target multiple types of pathogens to prepare for infectious threats. Azithromycin is one such broad-spectrum therapeutic that is both included in the University of Oxford's RECOVERY and excluded from the World Health Organization's SOLIDARITY trials. Here we review azithromycin's broad antibiotic, antimalarial, antiviral pharmacology and contextualise it against a broader history as the most disease-repositioned therapeutic of the macrolide class; we further evaluate azithromycin's clinical and socio-economic propriety for respiratory pandemics and delineate a model for its combinatorial mechanism of action against COVID-19 pneumonia. Twit Text FOAVip Azithromycin: The First Broad-spectrum Therapeutic ????J Transl Autoimmun http://www.kidney.de/pget.php?&tw=1&pmid=32839756 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32839756 #FOAvip English Wikipedia <ref>{{Cite pmid|32839756}}</ref> Azithromycin: The First Broad-spectrum Therapeutic #MMPMID32839756 Kruger D; Prathapan P J Transl Autoimmun 2020[Aug]; ä (ä): 100062 PMID32839756show ga The Strategic Plan for Biodefense Research by the U.S. Department of Health and Human Services demarcates the need for drugs which target multiple types of pathogens to prepare for infectious threats. Azithromycin is one such broad-spectrum therapeutic that is both included in the University of Oxford's RECOVERY and excluded from the World Health Organization's SOLIDARITY trials. Here we review azithromycin's broad antibiotic, antimalarial, antiviral pharmacology and contextualise it against a broader history as the most disease-repositioned therapeutic of the macrolide class; we further evaluate azithromycin's clinical and socio-economic propriety for respiratory pandemics and delineate a model for its combinatorial mechanism of action against COVID-19 pneumonia. äAzithromycin: The First Broad-spectrum Therapeutic (epmc).pdf DeepDyve Pubget Overpricing